Opthea Limited

OTCPK:CKDX.F Stock Report

Market Cap: US$529.1m

Opthea Valuation

Is CKDX.F undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Book vs Peers

  • Price-To-Book vs Industry

  • Price-To-Book vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of CKDX.F when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: CKDX.F ($0.44) is trading below our estimate of fair value ($13.6)

Significantly Below Fair Value: CKDX.F is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for CKDX.F?

Key metric: As CKDX.F barely has revenue we use its Price-To-Book Ratio for relative valuation analysis.

The above table shows the Price to Book ratio for CKDX.F. This is calculated by dividing CKDX.F's market cap by their current book value.
What is CKDX.F's PB Ratio?
PB Ratio-6.6x
Book-US$75.81m
Market CapUS$529.09m

Price to Book Ratio vs Peers

How does CKDX.F's PB Ratio compare to its peers?

The above table shows the PB ratio for CKDX.F vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PBEstimated GrowthMarket Cap
Peer Average1.5x
ARCT Arcturus Therapeutics Holdings
1.8x70.8%US$438.0m
GRAL GRAIL
0.2x35.7%US$507.0m
STOK Stoke Therapeutics
2.6x-2.8%US$599.1m
AUTL Autolus Therapeutics
1.6x50.6%US$745.1m
CKDX.F Opthea
n/a61.9%US$812.5m

Price-To-Book vs Peers: CKDX.F has negative equity and a Price-To-Book Ratio (-6.6x) compared to the peer average (1.5x).

Price to Book Ratio vs Industry

How does CKDX.F's PB Ratio compare vs other companies in the US Biotechs Industry?

62 CompaniesPrice / BookEstimated GrowthMarket Cap
GRAL GRAIL
0.2x35.7%US$507.04m
AMRN Amarin
0.4x-7.7%US$201.84m
NKTX Nkarta
0.4x-11.5%US$176.42m
ACET Adicet Bio
0.4x6.7%US$84.87m
CKDX.F is unprofitableIndustry Avg. 1.8xNo. of Companies83PB01.63.24.86.48+
62 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Book vs Industry: CKDX.F has negative equity and a Price-To-Book Ratio (-6.6x) compared to the US Biotechs industry average (1.8x).

Price to Book Ratio vs Fair Ratio

What is CKDX.F's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

CKDX.F PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio-6.6x
Fair PB Ration/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate CKDX.F's Price-To-Book Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst CKDX.F forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$0.44
US$0.60
+36.9%
61.9%US$1.07US$0.18n/a4
Nov ’25n/a
US$0.61
0%
61.9%US$1.09US$0.19n/a4
Oct ’25n/a
US$0.62
0%
61.9%US$1.11US$0.19n/a4
Sep ’25n/a
US$0.52
0%
64.4%US$1.07US$0.18n/a4
Aug ’25n/a
US$0.52
0%
64.4%US$1.07US$0.18n/a4
Jul ’25n/a
US$0.58
0%
64.9%US$1.08US$0.18n/a3
Jun ’25n/a
US$0.58
0%
63.4%US$1.08US$0.20n/a3
May ’25n/a
US$0.58
0%
65.0%US$1.09US$0.20n/a3
Apr ’25n/a
US$0.52
0%
82.9%US$1.12US$0.20n/a3
Mar ’25n/a
US$0.55
0%
86.8%US$1.22US$0.20n/a3
Feb ’25n/a
US$0.56
0%
86.8%US$1.24US$0.20n/a3
Jan ’25n/a
US$0.72
0%
71.7%US$1.29US$0.19n/a4
Dec ’24n/a
US$0.72
0%
71.7%US$1.29US$0.19n/a4
Nov ’24n/a
US$0.72
0%
71.7%US$1.29US$0.19n/a4
Oct ’24n/a
US$0.83
0%
77.6%US$1.70US$0.19n/a4
Sep ’24n/a
US$0.71
0%
99.4%US$1.71US$0.20n/a3
Aug ’24n/a
US$1.11
0%
53.6%US$1.88US$0.44n/a3
Jul ’24n/a
US$1.11
0%
53.6%US$1.88US$0.44n/a3
Jun ’24US$0.42
US$1.11
+164.3%
53.6%US$1.88US$0.44n/a3
May ’24n/a
US$1.11
0%
53.6%US$1.88US$0.44n/a3
Apr ’24n/a
US$1.11
0%
53.6%US$1.88US$0.44n/a3
Mar ’24n/a
US$1.11
0%
53.6%US$1.88US$0.44n/a3
Feb ’24n/a
US$1.15
0%
48.7%US$1.90US$0.54n/a3
Jan ’24n/a
US$1.15
0%
48.7%US$1.90US$0.54n/a3
Dec ’23n/a
US$1.16
0%
48.7%US$1.91US$0.54n/a3
Nov ’23n/a
US$1.16
0%
48.7%US$1.91US$0.54n/a3

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.

Discover undervalued companies

IQVIA Holdings

US$34.7b

Engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific.

IQV

US$194.38

7D

-8.1%

1Y

-7.2%

Collegium Pharmaceutical

US$959.4m

A specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management.

COLL

US$30.00

7D

-0.6%

1Y

15.5%

ANI Pharmaceuticals

US$1.1b

A biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada.

ANIP

US$55.10

7D

-7.9%

1Y

6.6%